Clinical stage biotech Affimed N.V. said Wednesday it is terminating its phase I program for AFM11 to focus on its innate immunity portfolio. The company had...
Source of shared Link
Affimed to end cancer program and focus on innate immunity portfolio, shares slide about 10% - MarketWatch
Source of shared Link